Focusing on innovation, unveiling new vision creation.

Link to: News

News

Link to: Projects

Projects

Link to: ESG-Sustainability

ESG

News

FDA approved the Phase-III clinical trial for Dry Eye Disease.

Sunhawk Vision received the approval of Australia patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).

Sunhawk Vision submitted the request to U.S. FDA for Orphan Drug Designation (ODD) for SHJ002 ophthalmic solution in treating recurrent corneal erosion in patients with Sjogren’s syndrome.

The eye drop SHJ002 for the treatment of dry eye disease has completed the submission of the Investigational New Drug (IND) application for phaseIII clinical trials to the U.S. FDA.

Sunhawk Vision received the approval of Japanese patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).

Sunhawk Vision has signed a contract with a U.S. pharmaceutical company with 30 years of manufacturing experience and is scheduled to manufacture clinical trial ophthalmic solution in the United States in August 2025.

The first study participant was recruited to the phase-2 myopia control trial.
Clinical trials

Preliminary results of Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome

The first study participant was recruited to the phase-2 myopia control trial.

The clinical data on the Phase-II trial for corneal erosion in patients with Sjogren’s syndrome (NCT06381986) were locked on May 5, 2025. The data were unblinded and under statistical analysis.

The first study participant was recruited to the phase-2 myopia control trial.

Sunhawk Vision has completed all subject assessments in its Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome.

The first study participant was recruited to the phase-2 myopia control trial.
Stock Market2

Sunhawk Vision has been registration as an Emerging Stock approved by the Taipei Exchange (OTC) Trading Center, meanwhile trading will commence from March 10, 2025.

The first study participant was recruited to the phase-2 myopia control trial.

The first study participant was recruited to the phase-2 myopia control trial.

The first study participant was recruited to the phase-2 myopia control trial.

FDA approved the Phase-III clinical trial for Dry Eye Disease.

Sunhawk Vision received the approval of Australia patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).

Sunhawk Vision submitted the request to U.S. FDA for Orphan Drug Designation (ODD) for SHJ002 ophthalmic solution in treating recurrent corneal erosion in patients with Sjogren’s syndrome.

The eye drop SHJ002 for the treatment of dry eye disease has completed the submission of the Investigational New Drug (IND) application for phaseIII clinical trials to the U.S. FDA.

Sunhawk Vision received the approval of Japanese patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).

Sunhawk Vision has signed a contract with a U.S. pharmaceutical company with 30 years of manufacturing experience and is scheduled to manufacture clinical trial ophthalmic solution in the United States in August 2025.

The first study participant was recruited to the phase-2 myopia control trial.
Clinical trials

Preliminary results of Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome

The first study participant was recruited to the phase-2 myopia control trial.

The clinical data on the Phase-II trial for corneal erosion in patients with Sjogren’s syndrome (NCT06381986) were locked on May 5, 2025. The data were unblinded and under statistical analysis.

The first study participant was recruited to the phase-2 myopia control trial.

Sunhawk Vision has completed all subject assessments in its Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome.

The first study participant was recruited to the phase-2 myopia control trial.
Stock Market2

Sunhawk Vision has been registration as an Emerging Stock approved by the Taipei Exchange (OTC) Trading Center, meanwhile trading will commence from March 10, 2025.

The first study participant was recruited to the phase-2 myopia control trial.

The first study participant was recruited to the phase-2 myopia control trial.

The first study participant was recruited to the phase-2 myopia control trial.

最新消息

Sunhawk Vision received the approval of Australia patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).

Read more

Sunhawk Vision submitted the request to U.S. FDA for Orphan Drug Designation (ODD) for SHJ002 ophthalmic solution in treating recurrent corneal erosion in patients with Sjogren’s syndrome.

Read more

The eye drop SHJ002 for the treatment of dry eye disease has completed the submission of the Investigational New Drug (IND) application for phaseIII clinical trials to the U.S. FDA.

Read more

Sunhawk Vision received the approval of Japanese patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).

Read more

Sunhawk Vision has signed a contract with a U.S. pharmaceutical company with 30 years of manufacturing experience and is scheduled to manufacture clinical trial ophthalmic solution in the United States in August 2025.

Read more

The clinical data on the Phase-II trial for corneal erosion in patients with Sjogren’s syndrome (NCT06381986) were locked on May 5, 2025. The data were unblinded and under statistical analysis.

Read more

Sunhawk Vision has completed all subject assessments in its Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome.

Read more

Taipei Office

© Copyright – Sunhawk Vision Biotech, Inc.

design by Morcept

© Copyright – Sunhawk Vision Biotech, Inc.
design by Morcept